Psilocybin or better known as magic mushroom has potential as a therapy for major depressive disorder. Nowadays you could find it in the form of how long do shroom pills last. The administration of two doses of psilocybin accompanied by psychotherapy showed a reduction in depressive symptoms in the patient. This finding was revealed by a research team from Johns Hopkins University through JAMA Psychiatry. These findings are based on a clinical trial that began in 2017. These clinical trials lasted until April 2019. This study involved adult participants with GDM who were not taking antidepressant drugs. They also had no history of psychotic disorders, attempted suicide, or hospitalization.
Giving psilocybin to participants appears to reduce the GRID-Hamilton Depression Rating (GRID-HAMD) scale significantly. Before therapy was given, the participants had a GRID-HAMD score of 23, which indicates moderate depression. After one week and one month of giving psilocybin therapy, the GRID-HAMD score decreased to 8. The score indicates mild depression. Overall, the research team found a 67 percent reduction in the severity of depressive symptoms one week after psilocybin therapy was given. This percentage increases to 71 percent in the fourth week. One week after administering psilocybin therapy, as many as 58 percent of participants no longer stated clinical depression. After four weeks, about 54 percent of the participants were no longer classified as depressed.
Further research is certainly needed to get a better understanding. However, in general, the clinical trials conducted by this research team support the use of psilocybin-assisted therapy for GDM. The speedy antidepressant result of psilocybin is related to that recorded for ketamine. However, the therapeutic effects of the two appear to be different. The effects of ketamine usually last from a few days to two weeks. Meanwhile, psilocybin therapy can provide a clinically significant antidepressant response for up to four weeks. 71 percent of participants proceeding to give a clinically notable response to follow-up at the 4th week. Currently, the gold standard in GDM therapy is psychotherapy or antidepressant drugs. However, a 2014 study in World Psychiatry determined that psychotherapy merged with antidepressants was more powerful than each one solely.